See more : CYduct Diagnostics, Inc. (CYDX) Income Statement Analysis – Financial Results
Complete financial analysis of Gelesis Holdings, Inc. (GLS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Gelesis Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Bank of America Corporation (BAC-PO) Income Statement Analysis – Financial Results
- Semantix, Inc. (STIXF) Income Statement Analysis – Financial Results
- Champion Real Estate Investment Trust (2778.HK) Income Statement Analysis – Financial Results
- Mitsui E&S Holdings Co., Ltd. (MIESF) Income Statement Analysis – Financial Results
- Western Magnesium Corporation (WMG.V) Income Statement Analysis – Financial Results
Gelesis Holdings, Inc. (GLS)
About Gelesis Holdings, Inc.
Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | 25.77M | 11.19M |
| Cost of Revenue | 27.56M | 9.98M |
| Gross Profit | -1.79M | 1.20M |
| Gross Profit Ratio | -6.95% | 10.75% |
| Research & Development | 18.61M | 12.87M |
| General & Administrative | 42.21M | 18.26M |
| Selling & Marketing | 56.92M | 52.78M |
| SG&A | 99.14M | 71.04M |
| Other Expenses | 2.27M | 2.27M |
| Operating Expenses | 120.02M | 86.18M |
| Cost & Expenses | 147.57M | 96.16M |
| Interest Income | 0.00 | 0.00 |
| Interest Expense | 991.00K | 1.36M |
| Depreciation & Amortization | 7.59M | 4.44M |
| EBITDA | -121.81M | -80.53M |
| EBITDA Ratio | -443.25% | -719.97% |
| Operating Income | -121.81M | -84.97M |
| Operating Income Ratio | -472.72% | -759.70% |
| Total Other Income/Expenses | 66.51M | -8.36M |
| Income Before Tax | -55.30M | -93.33M |
| Income Before Tax Ratio | -214.62% | -834.42% |
| Income Tax Expense | 480.00K | 17.00K |
| Net Income | -55.78M | -93.35M |
| Net Income Ratio | -216.48% | -834.57% |
| EPS | -0.79 | -16.34 |
| EPS Diluted | -0.79 | -16.34 |
| Weighted Avg Shares Out | 70.30M | 5.71M |
| Weighted Avg Shares Out (Dil) | 70.30M | 5.71M |
Gelesis to Report First Quarter 2022 Financial Results on May 12, 2022
Gelesis to Report First Quarter 2022 Financial Results on May 12, 2022
Gelesis Holdings: Advancing Biomimetic Superabsorbent Hydrogels For GI-Related Diseases
Gelesis Holdings, Inc. (GLS) CEO Yishai Zohar on Q4 2021 Results - Earnings Call Transcript
Gelesis® Reports Fiscal Year 2021 Results and Fiscal Year 2022 Financial Outlook
Gelesis to Report Full Year 2021 Financial Results on March 24, 2022
Source: https://incomestatements.info
Category: Stock Reports